Vutrisiran associated with better functional capacity in ATTR-CM
Vutrisiran appears to effectively conserve functional capacity and quality of life (QOL) in patients with ATTR-CM.
Vutrisiran appears to effectively conserve functional capacity and quality of life (QOL) in patients with ATTR-CM.
A new study reports that treatment with acoramidis decreases the rate of all-cause mortality and cardiovascular hospitalization in patients with ATTR-CM.
Gene silencing and antifibril therapy could stop disease progression and eliminate amyloid deposits in patients with ATTR-CM.
The barriers to treatment of ATTR-CM included lack of affordability, delayed diagnosis and underrepresented populations in clinical trials.
A case of transthyretin amyloid cardiomyopathy (ATTR-CM) presented with symptoms generally associated with a different heart condition.
The stroke volume index appears to have greater prognostic accuracy for mortality in ATTR-CM than traditional echocardiographic indexes.
Patients with asymptomatic ATTR-CM and high cardiac uptake could benefit from disease-modifying treatment, according to a new study.
Researchers looked at a patient with rheumatoid arthritis who developed transthyretin amyloid cardiomyopathy-mediated heart failure.
Researchers identified factors that can accurately predict patients with wild-type ATTR-CM who are at high risk of early death.
Researchers found no significant difference in the structure of amyloid fibrils accumulated in different organs in a patient with ATTR-CM.